Oxaliplatin

For research use only.

Catalog No.S1224 Synonyms: L-OHP

70 publications

Oxaliplatin Chemical Structure

Molecular Weight(MW): 397.29

Oxaliplatin is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Oxaliplatin has been cited by 70 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Oxaliplatin is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.
Features This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).[9]
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HKESC-2 NGHTbYFEgXSxdH;4bYNqfHliQYPzZZk> MUKw5qCUOTZywrFOwG0> NFPxUI81QMLiaB?= M4DYfmlEPTB;NT64xsDDucLiMD61JO69VQ>? NYrCVll[OjZ2N{S2PVM>
CaES-17 NXq0SZhPS3m2b4TvfIlkcXS7IFHzd4F6 NFflWXMx6oDVMU[wxsDPxE1? MmfrOFjDqGh? NUPzXWZiUUN3ME21MlXDqMLzwrCwMlIh|ryP NFvVbVEzPjR5NE[5Ny=>
SW480 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWC0PEBpyqB? NELrTZFKSzVyPUGuPFch|ryP MVSyOlI3QTd3OR?=
HCT116 NEjYcolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkT1OFghcMLi MVTJR|UxRTFzLki2JO69VQ>? NXrUfZA{OjZ{Nkm3OVk>
LoVo MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;TXGFDPDhiaNMg NXfqSopWUUN3ME25OE45OyEQvF2= MmPQNlYzPjl5NUm=
SK-BR-3 MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\SdXVKSzVyPUOxMlAhyrFiMD6xJO69VQ>? MWWyOlIyOTV7MR?=
MCF-7 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF3LkSgxtEhOC5|IN88US=> M1v6eFI3OjFzNUmx
MDA-MB-231 NWf0PIVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzMO3ZKSzVyPUKzMlEhyrFiMD6xJO69VQ>? MWeyOlIyOTV7MR?=
HCT116 p53+/+ M3\yfmZ2dmO2aX;uJGF{e2G7 NYDBflg{OS93IN88US=> MVmyOE81QCCq M2XKcYlv\HWlZYOgeJJidnOlcnnweIlwdmGuIILldJJme3Orb36gc4YhTFWWLV6= Mo\ZNlYzODh3MkO=
LoVo  Mmr1SpVv[3Srb36gRZN{[Xl? M4PaTlEwPSEQvF2= Mn2zNlQwPDhiaB?= NXfJcXZ{cW6mdXPld{B1emGwc3PybZB1cW:wYXygdoVxemW|c3nvckBw\iCGVWStUi=> M1zC[|I3OjB6NUKz
SNU-398 M{XRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTZwNdMgxtHDqDFwMTFOwG0> NIi3SGIzPjF4MESyPS=>
Hep-G2 MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TNUWlEPTB;MUOuNeKhyrIEoEGuOkDPxE1? NXPBZ2x2OjZzNkC0Nlk>
SNU-475 NYqyW4ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|Ux97zgM{Cg{txO MXeyOlE3ODR{OR?=
SNU-387 M4\4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJ3wrFCteKhOi55IN88US=> MV6yOlE3ODR{OR?=
HT29 NHjHdZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwOElCpOKyyqByLkKg{txO M2OzSlI3OTR6NUm2
HCT116 M3H2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHu3VmtKSzVyPUCuOFHDqMLzwrCwMlAzKM7:TR?= Ml7uNlYyPDh3OU[=
PA-1 NIT3OplE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVywMVIxKM7:TR?= MX6yOE81QCCq NY\PeG5rcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MmLxNlYyOzh4N{G=
OVCAR-5 NWmw[2tDS2WubDDWbYFjcWyrdImgRZN{[Xl? NXrrT5RJOC14MDFOwG0> MUSyOE81QC95MjDo M3fKc4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MnrqNlYyOzh4N{G=
SK-OV-3 Mn3TR4VtdCCYaXHibYxqfHliQYPzZZk> M361WFAuOTByIN88US=> MXiyOE81QC95MjDo M{n1bolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NFrselUzPjF|OE[3NS=>
PA-1 MWHGeY5kfGmxbjDBd5NigQ>? NYPKZ5Q4OTBizszNxsA> NFPrXHczPGh? M4nrVZRzcWepZYLld{B1cGVicILv[JVkfGmxbjDv[kB1gXCnIFmgTWZPeyCjbnSgZ4hmdW:taX7ldy=> NYDUTGhpOjZzM{i2O|E>
OVCAR-5 Mnr3SpVv[3Srb36gRZN{[Xl? MlXaN|Ah|ryP NYTQT29EPDiq NFT3TYt1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM> MmfINlYyOzh4N{G=
SK-OV-3 MYnGeY5kfGmxbjDBd5NigQ>? NIO3N3U2OCEQvF2= NX;XVYNqQTZiaB?= NGXXS|R1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM> M3ThdVI3OTN6Nkex
PA-1 NFPrdm5HfW6ldHnvckBCe3OjeR?= MVuxNEDPxE4EoB?= NEPWTI41QGh? M2Tk[5VxNXKnZ4XsZZRmeyC2aHWgd5Rz\XO|IHzp[4Fv\HNiZn;yJG5MKGOnbHytZYN1cX[jdHnu[{Bz\WOncITvdpMh[W6mIGTSRWlNKHKnY3XweI9zew>? M4flVFI3OTN6Nkex
OVCAR-5 MYLGeY5kfGmxbjDBd5NigQ>? NXPwNZo6OzBizszN NF;6e3Q1QGh? NHf0WoR2eC2{ZXf1cIF1\XNidHjlJJN1emW|czDsbYdidmS|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN? Mn;kNlYyOzh4N{G=
SK-OV-3 M2fzb2Z2dmO2aX;uJGF{e2G7 NVXPWW5VPTBizszN MmL3PVYhcA>? NFvnR4x2eC2{ZXf1cIF1\XNidHjlJJN1emW|czDsbYdidmS|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN? NHzFWG8zPjF|OE[3NS=>
PA-1 NFr5O3VHfW6ldHnvckBCe3OjeR?= NGr1UJUyOCEQvF5CpC=> M1PkUFI1cA>? MoHhdJJwdW:2ZYOgd4Vve2m2aY\peJkhd2Zib4\hdolidiClYYLjbY5wdWFidH:gUmsh[2WubD3t[YRq[XSnZDDjfZRwdHm|aYO= M{TQSlI3OTN6Nkex
OVCAR-5 NH3qT5VHfW6ldHnvckBCe3OjeR?= MnLvNlAh|ryPwrC= M{C0WlI1cA>? MljpdJJwdW:2ZYOgd4Vve2m2aY\peJkhd2Zib4\hdolidiClYYLjbY5wdWFidH:gUmsh[2WubD3t[YRq[XSnZDDjfZRwdHm|aYO= MnPqNlYyOzh4N{G=
SK-OV-3 M4j5PWZ2dmO2aX;uJGF{e2G7 NI\5PYk2OCEQvF5CpC=> MojMOFghcMLi NGrpWXpxem:vb4Tld{B{\W6|aYTpeol1gSCxZjDveoFzcWGwIHPhdoNqdm:vYTD0c{BPUyClZXzsMY1m\GmjdHXkJIN6fG:ueYPpdy=> MlzONlYyOzh4N{G=
CT26  MVnGeY5kfGmxbjDBd5NigQ>? MYS0JI1O NITh[pk1QCCqwrC= NYjofJYxcW6mdXPld{BifXSxcHjh[5k> M2fEeFI3OTN5MEGy
CT26  NGLlO|BHfW6ldHnvckBCe3OjeR?= MXm0JI1O NXfVcHc4PDhiaNMg MlvvbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVteyCxZjDheZRweGijZ4mtdoVt[XSnZDDwdo91\Wmwczygd5VkcCCjczDMR|MuUUluIFLlZ4xqdjFiYX7kJGFVTzV? MXWyOlE{PzBzMh?=
CT26  M{fvcWNmdGxiVnnhZoltcXS7IFHzd4F6 NGPFNIM1KG2P M2jtSFQ5KGkEoB?= MWfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlidH:gOVMvOiV? NYHwTY42OjZzM{ewNVI>
BE NU\vXFJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\QTWM2OD1|LkOzJO69VQ>? NHvHc3czPjB{M{C4OS=>
Colo205 NWnWNmQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;QNGlEPTB;Mz6zN{DPxE1? M{fUXVI3ODJ|MEi1
DLD1 Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mor2TWM2OD1{LkCxJO69VQ>? MkTKNlYxOjNyOEW=
HT29 MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTaTWM2OD1{Lk[5JO69VQ>? NVjsdlZuOjZyMkOwPFU>
HCT15 NUHKWWZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DZbWlEPTB;MT60N{DPxE1? MYWyOlAzOzB6NR?=
HCT116 Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHTXoxKSzVyPUGuNFQh|ryP M4TXW|I3ODJ|MEi1
HCT116p53- M4X3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjLTWM2OD1zLkC4JO69VQ>? MkOxNlYxOjNyOEW=
KM12 NFvVcG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHnTWM2OD12LkO3JO69VQ>? MVyyOlAzOzB6NR?=
LoVo NVTRVo5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLRSWFKSzVyPUGuNkDPxE1? NFXORnozPjB{M{C4OS=>
RKO M1;pUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTFwMkOg{txO NH[2N4szPjB{M{C4OS=>
SW480 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jkO2lEPTB;Mj64OkDPxE1? M37hVVI3ODJ|MEi1
SW620 NYnJ[3F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jyemlEPTB;Mz62PEDPxE1? NEnSfGkzPjB{M{C4OS=>
MC38 M1rvN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT0XY1xUUN3ME2yN{DPxE1iwsGgNi=> NXrH[HhDOjZyMESwPFQ>
HT29 NEPXNWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmOzTWM2OD14MzFOwG0hyrFiMUi= MnfaNlYxODRyOES=
DLD-1 M2rZcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf1cmpKSzVyPUOyMlIh|ryP M2TNbVI3ODB|MEi1
HT-29 Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{P1dGlEPTB;M{WuOkDPxE1? MYGyOlAxOzB6NR?=
SiHa MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPwSGFKSzVyPUCuPEDDuSByLkGg{txO MXSyOVgxOTByNx?=
S3 NHrvSoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fCeGlEPTB;NUOuOUDDuSBzLkWg{txO NYXG[HB7OjV6MEGwNFc>
AGS NGTZUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe5O5lKSzVyPUGwMlYh|ryP NYTnfmVLOjV5OEmwOVc>
MKN-45 NYPRc2h1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rTRWlEPTB;MUSuNEDPxE1? MVeyOVc5QTB3Nx?=
TMK-1 NXn3R|RlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHruO2hKSzVyPUKyMlYh|ryP NWf0d4dxOjV5OEmwOVc>
SCM-1 M4iwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF5LkWg{txO NGi4[5gzPTd6OUC1Oy=>
HCT-15 M2fOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXOblF3UUN3ME24MlY1KM7:TR?= NF\YPZozPTd4MUS3PS=>
DiFi NFHMOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTFyLkm1JO69VQ>? MkLkNlU4PjF2N{m=
DLD-1 NWe2emhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRThwNkWg{txO NF6x[lIzPTd4MUS3PS=>
COLO-320DM NF22S4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVWxd4pTUUN3ME21MlM5KM7:TR?= NGTrVIwzPTd4MUS3PS=>
SNU-175 NUHUfXplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PWO2lEPTB;MT61NUDPxE1? M3XVU|I2PzZzNEe5
HT-29 NXnxfVBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljHTWM2OD13LkKyJO69VQ>? MWmyOVc3OTR5OR?=
SW620 MUXGeY5kfGmxbjDBd5NigQ>? M1G1NVEx6oDLwsXnM41t MmrLNlTjiImq M2Pxb4lv[3KnYYPld{BNSzNvSVmgZYNkfW23bHH0bY9vKGGwZDDk[YNz\WG|ZYOgVFYzKGW6cILld5Nqd25? MYqyOVc1QTR{MB?=
SW480 MVTGeY5kfGmxbjDBd5NigQ>? MVmxNQKBkcL3Zz;tcC=> NUHLcpk2OjUkgJno MYPpcoNz\WG|ZYOgUGM{NUmLIHHjZ5VufWyjdHnvckBidmRiZHXjdoVie2W|IGC2NkBmgHC{ZYPzbY9v Mn7nNlU4PDl2MkC=
SW620 M4rNUGZ2dmO2aX;uJGF{e2G7 NY\xWmJnOTEkgJpCuYcwdWx? Mki4NlTjiImq NXzBcXJp\W6qYX7j[ZMh[2WubIXsZZIh[XW2b4DoZYdq[yCobIX4 NX7RdXZQOjV5NEm0NlA>
SW480 MXnGeY5kfGmxbjDBd5NigQ>? M4i5RlEx6oDLwsXnM41t MnXrNlTjiImq NFracWtmdmijbnPld{Bk\WyudXzhdkBifXSxcHjh[4lkKG[udYi= MX6yOVc1QTR{MB?=
A549 NEnPb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\wOWlEPTB;NT64JOKyKDBwNjFOwG0> Mn\ZNlU3OjV{NEO=
A549/CDDP NHO1fXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF6Lk[gxtEhOS5{IN88US=> MnP5NlU3OjV{NEO=
Panc-1 NE\1[XNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4LRNVI2NzVyIN88US=> NYD0[VVYOjRxNEigbC=> MX\pcohq[mm2czDwdo9tcW[ncnH0bY9vKG:oIGDDJINmdGy|IHnuJIEhe3mwZYLnbZN1cWNibXHucoVzKGOxbXLpcoVlKHerdHigW2E> NH;CfFUzPTR2NEmxOC=>
MIAPaCa-2 MUfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUn1eXhtOjVxNUCg{txO NFi5Z5gzPC92ODDo MnrNbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MkLrNlU1PDR7MUS=
SW1990 M4LRSmNmdGxiVnnhZoltcXS7IFHzd4F6 MXyyOU82OCEQvF2= M1vuN|I1NzR6IHi= MWjpcohq[mm2czDwdo9tcW[ncnH0bY9vKG:oIGDDJINmdGy|IHnuJIEhe3mwZYLnbZN1cWNibXHucoVzKGOxbXLpcoVlKHerdHigW2E> NXPmXZcyOjV2NES5NVQ>
HPDE NHX5ZmtE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFXDU2czPS93MDFOwG0> MmezNlQwPDhiaB?= M{TabYlvcGmkaYTzJJBzd2yrZnXyZZRqd25ib3[gVGMh[2WubIOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? NH3VfmUzPTR2NEmxOC=>
Panc-1 MmnuRZBweHSxc3nzJGF{e2G7 MWeyOgKBkcL3TR?= MmPkNlQhcA>? NGPzdZRqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD NHmzO2czPTR2NEmxOC=>
MIAPaCa-2 Moq1RZBweHSxc3nzJGF{e2G7 NYrQ[W1oOjYkgJpCuW0> MX[yOEBp MVzpcoR2[2W|IHHwc5B1d3OrczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MXSyOVQ1PDlzNB?=
Panc-1 Ml:ySpVv[3Srb36gRZN{[Xl? MVeyOgKBkcL3TR?= M3fxbFI1NzR6IHi= NH7ZcFdqdmS3Y3XzJINt\WG4YXflJI9nKFCDUmCsJINie3Cjc3WtPUwh[2G|cHHz[U05KGGwZDDjZZNx[XOnLURCpC=> MXyyOVQ1PDlzNB?=
MIAPaCa-2 MlOwSpVv[3Srb36gRZN{[Xl? NFnpPHgzPeLCidM1US=> NF73WlUzPC92ODDo M1fBcolv\HWlZYOgZ4xm[X[jZ3Wgc4YhWEGUUDygZ4F{eGG|ZT25MEBk[XOyYYPlMVgh[W6mIHPhd5Bie2VvM9Mg MlHXNlU1PDR7MUS=
SW480 Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\RO|IhcMLi NY\EcGplUUN3ME2xNE44yrF{LkK2JOK2\y:vTB?= NVz1[FRKOjV|NkC2N|E>
HCT116  NVvvNoo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYq3NkBpyqB? M4XodmlEPTB;Nj6yN:KyOC55NTFCuYcwdUx? MnWyNlU{PjB4M{G=
COC1 MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nhWWlEPTB;NE[uNlDDqMLzwrCzMlE1KM7:TR?= MV2yOVMxPzR2OB?=
SGC7901 NGHtbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXJTWM2OD1{MT63N:KhyrIEoEOuNFgh|ryP M2TKRVI2OzB5NES4
A549 NFzPUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjX[5VKSzVyPUWxMlA5yqEEsdMgNVAvQTZizszN NFzPTFczPTNyN{S0PC=>
HepG2 NYHVZ5ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTMWZhpUUN3ME2xOE4zPMLiwsJCpFEvQDJizszN M4DlNlI2OzB5NES4
MCF-7 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHsWotiUUN3ME2xOE4zPMLiwsJCpFEvQDJizszN MkT6NlU{ODd2NEi=
HCT-116 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTHSnl4UUN3ME22MlI1yqEEsdMgNk46PyEQvF2= MkHhNlU{ODd2NEi=
HT-29 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrlN3V1UUN3ME61NEDPxE1? NGn5R|AzPTNyN{S0PC=>
HEK293 NFvnSXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELIZZdKSzVyPUiuPFLDqMLzwrC1MlU6KM7:TR?= NWHQN3luOjV|MEe0OFg>
HUVEC M2fCNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPNUYFPUUN3ME2xNU4{OMLiwsJCpFEvODJizszN NIHkb3kzPTNyN{S0PC=>
SW480 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfsc|QyyqEQvF2= M3T4PFAuPzJiaB?= M1TV[IlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz NF\HRXMzPDl7N{S1NS=>
HT-29 NIfTbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWWxxsDPxE1? MmftNE04OiCq Ml7vbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MUSyOFk6PzR3MR?=
HCT116 NHvjOmRHfW6ldHnvckBCe3OjeR?= NInKfZozNzViwsXN NX20fYFHOjRxNEigbC=> M2flSpN2eHC{ZYPz[ZMhe3W{dnn2bY4hdVKQQTDlfJBz\XO|aX;u NITqUJIzPDd4MUSxNS=>
SW480  MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjuVodLPDhiaNMg M2nHd2lEPTB;MkCuPEB2\y:vTB?= M2LFPVI1PzJyNke1
SW620 M1LCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnTT|AyOC15MDDt[{9N M2K5d|I1NzR6L{eyJIg> MW\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MXuyOFY1PjNyNR?=
Caco2  M4TkeGZ2dmO2aX;uJGF{e2G7 M3jKOFMxyqEQvF2= MVGyOEBp M4XwdmROW09? NGjGdZRqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGhQNTFuIFHLVlFENCCjbnSgUnFQOQ>? M3\rTFI1PTV4NEG1
Caco2  NHm0clRHfW6ldHnvckBCe3OjeR?= MWGzM|ExNzNyIN88US=> MmS4NVYhcA>? MVzEUXNQ NXTSd|dlcW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLiQVvSNWMyNCCQUV:xMEBJVy1zLDDNVnAzNMLiYX7kUXJRO8LiZH;z[U1l\XCnbnTlcpRtgQ>? MVqyOFU2PjRzNR?=
Caco2 M1L4OWZ2dmO2aX;uJGF{e2G7 MVKzNE8yODEEoN88US=> Ml:2NVbDqGh? MlTXSG1UVw>? MX7hZ5RqfmG2ZYOgUpJnOg>? NIL0NlMzPDV3NkSxOS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
VEGFR-1 / NRP-1 ; 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin (0.2 and 2 μmol/L) in 1% MEM-FBS. Western blotting analysis showed that oxaliplatin treatment up-regulated VEGFR-1 and NRP-1 protein expression. 

p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416); 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin for 5, 15, 30, and 60 min. Western blotting showed that oxaliplatin induced Akt activation, with peak phosphorylation occurring at 60 min and decreased PTEN. Phospho-Src increased at 30 min.

p-Src(Y418) / p-FAK(Y861) ; 

PubMed: 19383922     


Src and FAK activation by Western blots were determined at various time periods after oxaliplatin treatment (2.5 µM) for HT29 and KM12-L4 cells, and representative of triplicate experiments. Densitometry represents a ratio of the phosphorylated form to th䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ

18790786 19383922
Immunofluorescence
E-cadherin / Vimentin; 

PubMed: 30787271     


Silencing ATXN2L reversed oxaliplatin-induced epithelial mesenchymal transition in MGC803 cells.

ATXN2L / G3BP1; 

PubMed: 30787271     


Under different concentrations and durations of oxaliplatin stimulation, the immunfluorescence staining expressions of ATXN2L and G3BP1 were enhanced by different levels, and ATXN2L coexpressed with G3BP1 in stress granules. 

30787271
Growth inhibition assay
Cell viability ; 

PubMed: 28339092     


Cell viability curve of BGC-823 and MKN-28 cells treated with oxaliplatin at different concentrations. 

28339092
In vivo

A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol

Cell Research:

[4]

- Collapse
  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method:

    The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control


    (Only for Reference)
Animal Research:

[6]

- Collapse
  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro Water 3 mg/mL warmed (7.55 mM)
DMF Insoluble
Ethanol '''0.01 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% glucose (with warming)
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage 2 years 4°C(in the dark) powder
1 week 4°C(in the dark) in solvent
Synonyms L-OHP
Smiles [Pt++].NC1CCCCC1N.[O-]C(=O)C([O-])=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04158349 Not yet recruiting Drug: Oxaliplatin|Drug: mFOLFIRI Colorectal Cancer|Appendiceal Cancer|Peritoneal Carcinoma University of Utah May 2020 Phase 1
NCT04003792 Not yet recruiting Drug: oxaliplatin|Drug: FOLFIRI Protocol|Drug: Bevacizumab Liver Metastasis Colon Cancer Rabin Medical Center January 2020 Phase 2
NCT04261920 Recruiting Drug: Huangqi Guizhi Wuwu decoction Oncology Jiangsu Famous Medical Technology Co. Ltd. January 3 2020 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is it ok to dissolve Oxaliplatin in DMSO?

  • Answer:

    Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Oxaliplatin | Oxaliplatin supplier | purchase Oxaliplatin | Oxaliplatin cost | Oxaliplatin manufacturer | order Oxaliplatin | Oxaliplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID